Detalhe da pesquisa
1.
Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study.
Lancet
; 403(10423): 271-281, 2024 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071986